How, and how efficiently, can we treat Chlamydia trachomatis infections in women?

Secondo Guaschino, Giuseppe Ricci

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Several antichlamydial active drugs are available for both non-pregnant and pregnant women, potentially allowing effective prevention of the consequences and transmission of infection. The choice of treatment regimen not only has to consider efficacy, but also side-effects, compliance and the cost of antibiotic drugs. In recent years there have been no significant changes to the guidelines for treating Chlamydia trachomatis infection as no new antibiotic has been included. Inclusion of a new antichlamydial drug in the guidelines must be supported by suitable, randomized trials. Furthermore, how much it will be used in clinical practice will also depend on considerations of a pharmacoeconomic nature.

Original languageEnglish
Pages (from-to)875-888
Number of pages14
JournalBest Practice and Research: Clinical Obstetrics and Gynaecology
Volume16
Issue number6
DOIs
Publication statusPublished - Dec 2002

Fingerprint

Chlamydia Infections
Chlamydia trachomatis
Guidelines
Anti-Bacterial Agents
Pharmaceutical Economics
Drug Costs
Infectious Disease Transmission
Pharmaceutical Preparations
Compliance
Pregnant Women
Therapeutics

Keywords

  • Antibiotics
  • Azithromycin
  • Chlamydia trachomatis
  • Drug therapy
  • Erythromycin
  • Female genital infections
  • Tetracycline

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this

How, and how efficiently, can we treat Chlamydia trachomatis infections in women? / Guaschino, Secondo; Ricci, Giuseppe.

In: Best Practice and Research: Clinical Obstetrics and Gynaecology, Vol. 16, No. 6, 12.2002, p. 875-888.

Research output: Contribution to journalArticle

@article{f8d5e87d03d5470ba11b1b822b0323a6,
title = "How, and how efficiently, can we treat Chlamydia trachomatis infections in women?",
abstract = "Several antichlamydial active drugs are available for both non-pregnant and pregnant women, potentially allowing effective prevention of the consequences and transmission of infection. The choice of treatment regimen not only has to consider efficacy, but also side-effects, compliance and the cost of antibiotic drugs. In recent years there have been no significant changes to the guidelines for treating Chlamydia trachomatis infection as no new antibiotic has been included. Inclusion of a new antichlamydial drug in the guidelines must be supported by suitable, randomized trials. Furthermore, how much it will be used in clinical practice will also depend on considerations of a pharmacoeconomic nature.",
keywords = "Antibiotics, Azithromycin, Chlamydia trachomatis, Drug therapy, Erythromycin, Female genital infections, Tetracycline",
author = "Secondo Guaschino and Giuseppe Ricci",
year = "2002",
month = "12",
doi = "10.1053/beog.2002.0336",
language = "English",
volume = "16",
pages = "875--888",
journal = "Best Practice and Research in Clinical Obstetrics and Gynaecology",
issn = "1521-6934",
publisher = "Bailliere Tindall Ltd",
number = "6",

}

TY - JOUR

T1 - How, and how efficiently, can we treat Chlamydia trachomatis infections in women?

AU - Guaschino, Secondo

AU - Ricci, Giuseppe

PY - 2002/12

Y1 - 2002/12

N2 - Several antichlamydial active drugs are available for both non-pregnant and pregnant women, potentially allowing effective prevention of the consequences and transmission of infection. The choice of treatment regimen not only has to consider efficacy, but also side-effects, compliance and the cost of antibiotic drugs. In recent years there have been no significant changes to the guidelines for treating Chlamydia trachomatis infection as no new antibiotic has been included. Inclusion of a new antichlamydial drug in the guidelines must be supported by suitable, randomized trials. Furthermore, how much it will be used in clinical practice will also depend on considerations of a pharmacoeconomic nature.

AB - Several antichlamydial active drugs are available for both non-pregnant and pregnant women, potentially allowing effective prevention of the consequences and transmission of infection. The choice of treatment regimen not only has to consider efficacy, but also side-effects, compliance and the cost of antibiotic drugs. In recent years there have been no significant changes to the guidelines for treating Chlamydia trachomatis infection as no new antibiotic has been included. Inclusion of a new antichlamydial drug in the guidelines must be supported by suitable, randomized trials. Furthermore, how much it will be used in clinical practice will also depend on considerations of a pharmacoeconomic nature.

KW - Antibiotics

KW - Azithromycin

KW - Chlamydia trachomatis

KW - Drug therapy

KW - Erythromycin

KW - Female genital infections

KW - Tetracycline

UR - http://www.scopus.com/inward/record.url?scp=0036884224&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036884224&partnerID=8YFLogxK

U2 - 10.1053/beog.2002.0336

DO - 10.1053/beog.2002.0336

M3 - Article

C2 - 12473288

AN - SCOPUS:0036884224

VL - 16

SP - 875

EP - 888

JO - Best Practice and Research in Clinical Obstetrics and Gynaecology

JF - Best Practice and Research in Clinical Obstetrics and Gynaecology

SN - 1521-6934

IS - 6

ER -